Cytosorbents Announces The Regulatory Approval Of Cytosorb In Taiwan For Extracorporeal Removal Of Cytokines (e.g. Cytokine Storm, Sepsis), Bilirubin (e.g. Liver Disease), And Myoglobin (e.g. Trauma) From A Patient's Circulating Blood
Portfolio Pulse from Benzinga Newsdesk
Cytosorbents has received regulatory approval in Taiwan for its CytoSorb device, which is used for the extracorporeal removal of cytokines, bilirubin, and myoglobin from blood. The device is also approved for removing antithrombotic drugs during cardiothoracic surgery to reduce bleeding. CytoSorb will be distributed in Taiwan by Hemoscien Corporation.
June 24, 2024 | 11:19 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Cytosorbents' CytoSorb device has received regulatory approval in Taiwan for multiple medical applications, including the removal of cytokines, bilirubin, myoglobin, and antithrombotic drugs. This approval could lead to increased sales and market expansion in Asia.
The regulatory approval in Taiwan opens a new market for Cytosorbents, potentially increasing sales and revenue. The approval for multiple uses, including critical applications like cytokine storm and sepsis, enhances the product's marketability.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100